AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products.
AbbVie’s Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.
Cramer Says This Major Healthcare Stock Is ‘Ridiculously Cheap And Doing So Many Great Things’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. "It’s a very steady story," he noted.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
ImmunoGen Presented Findings From Newly Diagnosed Acute Myeloid Leukemia Cohorts In Phase 1b/2 Study Of Pivekimab Sunirine In Combination With Azacitidine And Venetoclax At ASH 2023
Pivekimab Triplet Demonstrates Encouraging CR, Composite CR, and MRD Negativity Rates; Broad Anti-Leukemia Activity Observed Across All Molecular Subsets Evaluated
Pivekimab-Containing Triplet Well-Tolerated with
AbbVie’s New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals
Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the transact
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE (Mirvetuximab Soravtansine-Gynx) in Platinum-Resistant Ovarian Cancer
ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has filed the